Trinity Biotech plc
TRIB
$0.94
$0.022.51%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -31.64% | 18.09% | 13.99% | -6.54% | -28.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.64% | 18.09% | 13.99% | -6.54% | -28.63% |
| Cost of Revenue | -38.49% | 23.91% | 13.99% | -32.38% | 17.33% |
| Gross Profit | -19.55% | 6.79% | 14.00% | 1,200.91% | -96.30% |
| SG&A Expenses | 8.64% | 20.71% | -18.75% | 49.15% | -15.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 81.69% | -6,900.00% | 97.67% |
| Total Operating Expenses | -20.99% | 33.82% | -2.37% | -11.00% | 6.48% |
| Operating Income | -80.14% | -94.43% | 58.71% | 22.98% | -430.49% |
| Income Before Tax | 17.64% | -187.17% | 62.99% | 34.93% | -723.74% |
| Income Tax Expenses | 324.43% | 19,600.00% | 50.94% | 11,000.00% | -99.20% |
| Earnings from Continuing Operations | 11.69% | -197.96% | 63.17% | 32.72% | -839.85% |
| Earnings from Discontinued Operations | -- | -19,000.00% | -- | -100.10% | 3,696.55% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.69% | -208.22% | -12.84% | 24.86% | -777.14% |
| EBIT | -80.14% | -94.43% | 58.71% | 22.98% | -430.49% |
| EBITDA | -54.95% | -109.92% | 57.39% | 16.24% | -300.43% |
| EPS Basic | 55.15% | -78.22% | 8.72% | 25.30% | -471.36% |
| Normalized Basic EPS | 42.18% | -- | 47.17% | -- | -- |
| EPS Diluted | 43.97% | -78.40% | 8.72% | 25.69% | -493.33% |
| Normalized Diluted EPS | 42.18% | -- | 47.17% | -- | -- |
| Average Basic Shares Outstanding | 96.86% | 73.21% | 23.62% | 0.58% | 82.32% |
| Average Diluted Shares Outstanding | 96.87% | 73.22% | 23.62% | 0.58% | 74.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |